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Noonan syndrome (NS) is a developmental disorder characterized by short stature, facial dysmorphia, congenital heart
disease, and multiple skeletal and hematologic defects. NS is an autosomal dominant trait and is genetically heteroge-
neous. Gain of function of SHP-2, a protein tyrosine phosphatase that positively modulates RAS signaling, is observed
in nearly 50% of affected individuals. Here, we report the identification of heterozygous KRAS gene mutations in two
subjects exhibiting a severe NS phenotype with features overlapping those of cardiofaciocutaneous and Costello syn-
dromes. Both mutations were de novo and affected exon 6, which encodes the C-terminal portion of KRAS isoform B
but does not contribute to KRAS isoform A. Structural analysis indicated that both substitutions (Val152Gly and
Asp153Val) perturb the conformation of the guanine ring–binding pocket of the protein, predicting an increase in the
guanine diphosphate/guanine triphosphate (GTP) dissociation rate that would favor GTP binding to the KRASB isoform
and bypass the requirement for a guanine nucleotide exchange factor.
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Noonan syndrome (NS [MIM 163950]) is a clinically var-
iable disorder defined by short stature, facial dysmorph-
ism, multiple skeletal defects, and congenital heart dis-
ease.1–3 The distinctive facial features consist of a broad
forehead, hypertelorism, down-slanting palpebral fissures,
high-arched palate, and low-set, posteriorly rotated ears.
Cardiac involvement is present in up to 90% of affected
individuals, with pulmonic stenosis, hypertrophic cardio-
myopathy, atrioventricular septal defects, and aortic co-
arctation representing the most common lesions.4 Addi-
tional relatively recurrent features of NS are webbed and/
or short neck, mental retardation, cryptorchidism, and he-
matologic anomalies. Although precise epidemiological
data are not available, the prevalence of NS is estimated
to be between 1 in 1,000 and 1 in 2,500 live births.5
NS is an autosomal dominant trait and is genetically
heterogeneous.6 Using a positional candidacy approach,
we established PTPN11 as the NS disease gene residing at
NS1 (12q24),7 and studies by our groups and others have
demonstrated that mutations in PTPN11 account for
nearly 50% of affected individuals.5 The PTPN11 gene en-
codes the cytoplasmic protein tyrosine phosphatase SHP-
2, a widely expressed signal transducer with crucial roles
in the cellular response to growth factors, hormones, and
cytokines.8 Accumulating genetic, modeling, and bio-
chemical data indicate that NS-causing PTPN11 mutations
promote SHP-2 gain of function.7,9–12 In contrast, a limited
number of germline PTPN11 missense mutations that seem
to engender dominant negative effects cause the pheno-
typically related LEOPARD syndrome (MIM 151100).12–15 Fi-
nally, a distinct class of somatic PTPN11 mutations pro-
moting stronger activation of SHP-2 has been identified
as contributing to leukemogenesis.11,12,16–18
SHP-2 is an essential component of the machinery re-
quired for the activation of the RAS-mediated intracellu-
lar signaling pathways, and converging data indicate that
germline and somatic PTPN11 mutations cause deregu-
lation of RAS function.15,16,19–22 RAS proteins act as GDP/
GTP–regulated molecular switches to control intracellular
signal flow.23,24 They exhibit high affinity for both GDP
and GTP and low GTPase activity. GDP/GTP cycling is
controlled by GTPase-activating proteins (GAPs), which
accelerate the intrinsic GTPase activity, and by guanylyl-
exchanging factors (GEFs), which promote release of GDP.
RAS proteins cycle from a GDP-bound inactive state to a
GTP-bound active state, the latter allowing signal flow by
protein interaction with multiple downstream transduc-
ers. RAS proteins share a structure that includes a con-
served domain (residues 1–165), known as the “G do-
main,” which is required for signaling function, and a less
conserved C-terminal tail, called the “hypervariable re-
gion,” that guides posttranslational processing and plasma
membrane anchoring (fig. 1A). Within the conserved re-
gion, five motifs (G-1 to G-5) direct the GTP/GDP binding
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Figure 1. Heterozygous KRAS missense mutations causing a severe Noonan syndrome phenotype with features overlapping those of
CFC and CS. A, Schematic representation of the structural and functional domains defined within RAS proteins.25 The conserved domain
(G domain) is indicated, together with the motifs required for signaling function. The hypervariable region is shown (gray), as is the
C-terminal motifs that direct posttranslational processing and plasma membrane anchoring (dark gray). The arrow indicates the location
of affected residues. B, KRAS gene organization and transcript processing that produces the alternative KRAS isoforms A and B (Gene
accession numbers NC_000012, NM_004985, and NM_033360). The numbered black and gray boxes indicate the invariant coding exons
and the exons undergoing alternative splicing, respectively. KRASB mRNA results from exon 5 skipping. In KRASA mRNA, exon 6 encodes
the 3′ UTR. The arrows indicate locations of mutations. C, DHPLC elution profiles (left) and electropherograms (right) of KRAS exon 6
PCR products showing the de novo heterozygous 455TrG (above) and 458ArT (below) changes. D, Dysmorphic facial features of individual
2 (with Asp153Val).
and exchange and the GTP hydrolysis.25 Furthermore, two
tracts, usually denoted as “Switch I” (residues 32–38) and
“Switch II” (residues 59–67), undergo major conforma-
tional changes on GTP/GDP exchange and mediate bind-
ing to effectors, GAPs, and GEFs.24,26,27
Given the link between the functions of SHP-2 and RAS,
we hypothesized that other genes encoding for proteins
functioning as transducers in RAS signaling might be im-
plicated in NS pathogenesis. Here, we report the identi-
fication of heterozygous KRAS gene mutations in a small
percentage of subjects exhibiting a severe NS phenotype.
Eighty-seven subjects with NS and eight subjects with
cardiofaciocutaneous (CFC) syndrome (MIM 115150)
were included in the study. All the individuals were of
European origin and lacked a PTPN11 coding-sequence
mutation12 (M.T., B.D.G., and B.D., unpublished data). In-
formed consent for genetic analyses was obtained from
all subjects considered in the study. For the vast majority
of these individuals, clinical features satisfied diagnostic
criteria for NS28 and CFC syndrome,29 but a few subjects
who did not have features sufficient to make a definitive
diagnosis were also considered. Genomic DNA was iso-
lated from peripheral blood leukocytes, and the entire
KRAS sequence coding for both the KRASA and the KRASB
isoforms (exons 2–6) (fig. 1B) was screened for mutations.
Primer pairs designed to amplify exons, exon/intron
boundaries, and short intron flanking stretches are listed
in table 1. The entire coding sequences of the NRAS, HRAS,
and DUSP6 genes, as well as the NF1 genomic portion
coding for the putative cysteine/serine–rich (exons 11–17)
and RASGAP (exons 21–27) domains of neurofibromin,
were also screened for mutations. Primer sequences and
PCR conditions are available on request. Mutation analysis
of the amplimers was performed with denaturing high-
performance liquid chromatography (DHPLC) by use of
the Wave 2100 System (Transgenomic) at column tem-
peratures recommended by Navigator software, version
1.5.4.23 (Transgenomic). Amplimers with abnormal de-
naturing profiles were purified (Microcon PCR [Millipore])
and were sequenced bidirectionally using the ABI BigDye
Terminator Sequencing Kit v.1.1 (Applied Biosystems) and
ABI Prism 310 Genetic Analyzer (Applied Biosystems). Pa-
ternity was confirmed by STR genotyping (AmpF/STR
Identifiler PCR amplification kit [Applied Biosystems]).
Structural analyses and molecular graphics were per-
formed using the program MOLMOL.30
Mutation analysis allowed the identification of hetero-
zygous KRAS mutations in two individuals (fig. 1C). Both
mutations were missense and affected exon 6, which en-
codes the C-terminal portion of KRAS isoform B.
A TrG transversion at position 455, predicting the sub-
stitution of Val152 by a glycine residue (Val152Gly), was
identified in a 1-year-old girl who had macrocephaly with
high and broad forehead, curly and sparse hair, hyperte-
lorism, strabismus, epicanthic folds, down-slanting pal-
pebral fissures, hypoplasic nasal bridge with bulbous tip
of the nose, high palate and macroglossia, low-set and
posteriorly rotated ears, short neck with redundant skin,
wide-set nipples, and umbilical hernia. She was born at
32 wk of gestation by cesarean section after a pregnancy
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Table 1. Primer Pairs and Annealing Temperatures (Tann) Used to Amplify
the Entire KRAS Coding Sequence and the Size of PCR Products
Exon
Primer Sequence
(5′r3′)
Tann
(C)
Product
Length
(bp)Forward Reverse
2 GATACACGTCTGCAGTCAACTG GGTCCTGCACCAGTAATATGC 60 340
3 GGTGCACTGTAATAATCCAGACT CATGGCATTAGCAAAGACTCA 56 300
4 GGTGTAGTGGAAACTAGGAATTAC GACATAACAGTTATGATTTTGCAG 58 344
5a CTCAAGCTCATAATCTCAAACTTCT GTAGTTCTAAAGTGGTTGCCACC 58 305
6a GACAAAACACCTATGCGGATGA GCTAACAGTCTGCATGGAGCA 62 429
a Exons 5 and 6 encode the C-terminal portions of KRAS isoforms A and B, respectively
(fig. 1B).
complicated by a cystic hygroma detected at 12 wk and
polyhydramnios at 30 wk. At birth, her weight was 2.550
kg (3 SD), length was 43 cm (0.5 SD), and head cir-
cumference was 32.5 cm (2 SD), and she showed edema
of lower limbs. Clinical examination at age 1 year showed
severe failure to thrive because of poor intake, with
weight, length, and head circumference at 5 SD, 5 SD,
and 1 SD, respectively. No skin anomaly was noted, and
no cardiac defect was documented by echocardiographic
examination. The phenotype was compatible with a se-
vere NS condition with features overlapping Costello syn-
drome (CS [MIM 218040]) (polyhydramnios, neonatal ma-
crosomia and macrocephaly, loose skin, and severe failure
to thrive) and, to a lesser extent, CFC syndrome (macro-
cephaly and sparse hair).
An ArT change at position 458, predicting the substi-
tution of the adjacent aspartic acid residue by valine
(Asp153Val), was observed in a 14-year-old girl with NS
and some features of CFC syndrome (fig. 1D). She had
short stature and growth retardation with delayed bone
age, cardiac defects (moderate ventricular hypertrophy,
mild pulmonic stenosis, and an atrial septal defect), dys-
morphic features (hypertelorism, down-slanting palpebral
fissures, strabismus, low-set and thick ears, relative mac-
rocephaly with high forehead, and a depressed nasal
bridge), short and mildly webbed neck, wide-set nipples,
and developmental delay. There was hyperpigmentation
of the skin and a large cafe´-au-lait spot on the face. The
creases of the hands and feet were deep. There was no
keratosis or ichthyosis. The nails and teeth were normal.
The hair was dry, thick, and without fracture and was wavy
but not curly. Abnormalities of the extremities included
cubitus valgus and joint hyperextensibility but not cli-
nodactyly. Her gestation was complicated by polyhydram-
nios. She had feeding difficulties until age 4 years and
subsequently experienced cyclic vomiting. She had a sin-
gle seizure, at age 6 years. Application of the CFC index,
a comprehensive scoring system developed to aid in di-
agnosing this disorder,29 yielded a score of 9.483, which
is just below the 5th percentile among patients with CFC.
Genotyping of parental DNAs confirmed paternity in
both families and demonstrated the de novo origin of the
mutations. Analysis of genomic DNA obtained from buc-
cal cells of the affected individuals documented the oc-
currence of mutations, indicating that both lesions were
germline events.
Val152 and Asp153 reside far from the portion of RAS typ-
ically altered in cancer,31 which suggests a different path-
ogenetic mechanism for NS. To explore this, we used crys-
tallographic information available on RAS family proteins.
Although the crystallographic structure of KRAS per se has
not been resolved, the available structures for other mem-
bers of the RAS family are largely superimposable. The
three-dimensional structures of HRAS (Protein Data Bank
codes 4Q21 [for GDP-HRAS] and 5P21 [for GTP-HRAS])
were considered in our analysis because many structures
of this protein have been resolved, including those of can-
cer-related mutants and complexes with GEF and GAP
proteins. HRAS is 94% homologous to KRAS isoform B
within the G domain.25 In HRAS, a glutamic acid residue
replaces Asp153 in KRAS. We assumed, however, that the
structure of this region was retained, because the substi-
tution was conservative and Glu153 and Asp153 are almost
equally represented among RAS proteins. Moreover, the
structure of RRAS (Protein Data Bank code 2FN4), which
has an aspartic acid residue at this position, shows almost
no structural alteration (fig. 2A). The mutated residues
Val152 and Asp153 are located at the N-terminus of the a-
helix (a5) spatially close to the G-5 region (residues 145–
147)25 (fig. 2B). The conformation of this region, which
constitutes part of the guanine-binding pocket, is margin-
ally affected by GDP/GTP switching (fig. 2C). The guanine
binding is maintained by an H-bonding network involv-
ing residues Asp119 and Ala146, which interact with the pu-
rine ring, and residues Gly13, Val14, Asn116, Lys117, Thr144,
and Ser145, which strengthen those interactions. Val152
and Asp153 contribute to stabilizing the guanine-binding
pocket. The side chain of Val152 participates in the stabi-
lization of a very tight hydrophobic core with residues
Leu19, Leu23, and Ala146 and the aliphatic chains of Gln22
and Arg149 (fig. 2B). The interactions with these amino
acids strongly guide the orientation of the a5 helix and,
as a consequence, of the loop containing the G-5 tract
involved in the interaction with the purine ring. The in-
troduction of a glycine residue at position 152 is predicted
to affect the stability of that hydrophobic core. In addi-
tion, this change would endow the peptide chain with
higher flexibility due to the presence of a Gly151Gly152 mo-
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Figure 2. Structural analyses. A, Superimposition of the crystallographic structures of HRAS (yellow) and RRAS (light blue), in the
region encompassing the b6 strand and a5 helix. The side chain of HRAS residues Arg149 (b6-a5 loop) and Glu153 (a5) and the
corresponding RRAS residues Arg176 and Asp180 are shown as a stick model. B, Crystallographic structure of GTP-HRAS32 showing the
interactions of residues 152 and 153. The side chain of Val152 (red surface) participates in a hydrophobic core involving residues Leu19,
Gln22, and Leu23 (gray surfaces); Ala146 (pink surface); and Arg149 (semitransparent yellow surface). The side chains of residues 149 and
153, forming a salt bridge, are shown as a stick model. The yellow dashed line indicates the hydrogen bond formed by the N-H of the
Ala146 backbone and the O6 atom (red stick) of the GTP molecule (blue sticks). C, Superimposition of the crystallographic structures of
GTP-HRAS32 (light blue) and GDP-HRAS33 (yellow) complexes. A ribbon representation is used for the protein backbone, whereas GDP
and GTP are shown as a stick model. The positions of the mutated residues (N-terminus of the a5 helix) and the G-5 motif are shown
in red and pink, respectively. Regions assuming a different conformation in the two complexes (Switch I [residues 32–38] and Switch
II [residues 59–67]) are shown in orange (in GDP-HRAS) and blue (in GTP-HRAS).
tif.34 Glu153 forms a salt bridge with Arg149 (fig. 2B), an
interaction that is retained in the comparable Asp residue
in RRAS protein, with a shorter distance between the
charged groups (fig. 2A). Loss of this salt bridge, caused
by the Asp153Val mutation, is predicted to destabilize the
conformation of the loop connecting the a5 and b6 tracts
(residues 144–151). Overall, these observations strongly
indicate that the Val152Gly and Asp153Val substitutions
destabilize the conformation of domains that contribute
extensively to the interaction of KRAS with the GTP/GDP
guanine ring and, consequently, are predicted to affect
binding to both GTP and GDP. Since these residues are
also involved in the binding of GTP-RAS with the human
GEF protein SOS,35 we cannot exclude the possibility that
additional mechanisms, including disruption of possible
regulatory interactions with GEF proteins, might also con-
tribute to the pathological effects of these mutations.
Since the 455TrG and 458ArT changes resided close to
the splice-acceptor site, we considered the possibility of
disruptive effects on an exonic splicing enhancer (ESE)
site, using an informatics approach. ESEfinder analysis36
identified a single site for the splicing factor SC35 (posi-
tions 13–20), which was not altered by these mutations.
We cannot exclude the possibility that the mutations al-
tered a site for an as-yet-unidentified ESE.
Following the discovery of PTPN11 mutations as a major
underlying cause of NS and LEOPARD syndrome,7,13,14
other developmental disorders clinically related to NS
have been demonstrated to be caused by defects in genes
that encode proteins functionally related to SHP-2, in-
cluding NF1 mutations and/or deletions in neurofibro-
matosis-Noonan syndrome (NFNS [MIM 601321]),37,38
HRAS mutations in CS,39 and, most recently, BRAF, MEK1,
and MEK2 mutations in CFC syndrome.40 Here, we doc-
umented that KRAS gene mutations affecting KRAS iso-
form B can cause a severe form of NS, with a phenotype
including features of CS and CFC syndrome. Studies pub-
lished while our work was in review confirmed indepen-
dently the causative role of KRAS mutations in NS and
CFC syndrome pathogenesis.41,42 Although the initial find-
ing concerning PTPN11 in NS implicated signaling down-
stream of RAS, it was unclear whether one or more path-
ways were affected. Taken together, the newer genetic
findings specifically implicate perturbed signaling through
the mitogen-activated protein kinase (MAPK) cascade. NS,
LEOPARD syndrome, CFC syndrome, CS, and NFNS can
now be grouped as developmental disorders resulting from
mutations in functionally related genes. Although a sig-
nificant portion of NS cases remain unexplained geneti-
cally, it appears highly likely that several additional genes
related to RAS/MAPK signal transduction will ultimately
be implicated.
RAS mutations associated with cancer generally upreg-
ulate RAS function by impairing the switch between the
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active and inactive conformation, favoring a shift in the
equilibrium toward the former.31,43,44 The same is true of
HRAS mutations causing CS39 and a few KRAS mutations
recently identified in NS42 and CFC syndrome.41 The NS-
associated KRAS mutations described in this report, one
of which was independently reported elsewhere,41,42 are
predicted to represent a novel gain-of-function mecha-
nism. This appears to stem from an increased rate of GDP-
GTP exchange related to a reduced affinity for GDP and
GTP. This assertion is supported by biochemical data45–48
from related RAS mutants characterized by substitutions
involving residues Asn116, Asp119, and Thr144. In particular,
biochemical and functional characterization of two HRAS
mutants (Asp119Asn and Thr144Ile) demonstrated that an
increase in rates of dissociation of GDP/GTP from the pro-
tein does not prevent the mutant RAS proteins from bind-
ing GTP in vivo and inducing transformation.49 The mech-
anism leading to this gain-of-function effect has been
characterized. Briefly, the inactive complex between wild-
type RAS and GDP is normally stable, requiring interaction
with GEF proteins for its dissociation. Mutations desta-
bilizing the GDP-bound state favor spontaneous dissoci-
ation of this complex. In these mutants, unbound RAS
tends to complex with GTP, because GDP and GTP have
similar dissociation constants47 but GTP has a significantly
higher concentration in the cytoplasm (GTP:GDP ratio of
25:1).50 On the basis of our structural analysis and these
related biochemical data, we suggest that the Val152Ala
and Asp153Val substitutions perturb the conformation of
the guanine ring-binding pocket, increasing the GDP/GTP
dissociation rate. This would shift the equilibrium toward
the GTP-bound, active form and bypass the requirement
for a GEF. These mutations would define a novel class of
activating lesions that are inherited germline and that per-
turb development. To our knowledge, they have not been
documented to occur as somatic lesions contributing to
human hematologic malignancies or solid tumors. Func-
tional studies to verify this hypothesis are in progress.
Both KRAS mutations identified in this study affected
exon 6, which contributes to KRASB but not to KRASA.51
KRASA and KRASAB differ at their C-termini, regions
subjected to posttranslational modifications.52 Similar to
HRAS and NRAS, KRASA is palmitoylated at cysteine res-
idues upstream of the conserved CAAX motif, which are
replaced with a polylysine stretch in KRAS isoform B. This
differential processing has profound functional effects,
leading to alternative trafficking pathways to the plasma
membrane and distinct membrane localization.51 Recent
evidence demonstrates that the two KRAS isoforms play
distinct roles in development. While KRASB is ubiqui-
tously expressed in embryonic and adult tissues, KRASA
expression is restricted temporally and spatially and is
not expressed in the adult heart.53 Consistent with these
data, loss of both KRAS isoforms is embryonic lethal,54,55
whereas absence of only KRASA does not perturb devel-
opment.53 Although KRAS mutations affecting domains
shared by the two isoforms can cause NS and CFC
syndrome,41,42 the identification of exon 6 mutations doc-
uments that isolated KRASB gain of function is sufficient
for disease pathogenesis—further evidence that KRAS iso-
form B plays the major role in development. Additional
studies are required to delineate the phenotypic spectrum
resulting from germline KRAS mutations as well as their
molecular diversity and functional consequences for in-
tracellular signaling and development.
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